CD4 and diabetes mellitus: The current results are consistent with empagliflozin modulating levels of inflammatory molecules (20, 22, 24) and may potentially lower inflammation in diabetes by decreasing glucose uptake into CD4+ T cells, resulting in e.g. decreased IFNγ release from the cells.